Smith & Nephew PLC
SNN
Company Profile
Business description
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound care solutions. Roughly 41% of the UK-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 29% of revenue is from the advanced wound therapy segment. Over half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Contact
Hatters Lane
Building 5, Croxley Park
WatfordHertfordshireWD18 8YE
GBRT: +44 1923477100
Sector
Healthcare
Stock type
Defensive
Industry
Medical Devices
Fiscal Year End
31 December 2025
Employees
18,000
Stocks News & Analysis
video
Do you qualify as 'rich'?
Morningstar's Sim Mody speaks with Mark LaMonica about the varying definitions of rich.
stocks
Megatrend Investing 2025 and beyond: ASX players to capitalise on the clean energy transition
Find out how you can benefit from global megatrends.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,628.40 | 161.30 | -1.84% |
| CAC 40 | 7,825.43 | 124.74 | -1.57% |
| DAX 40 | 21,351.37 | 380.68 | -1.75% |
| Dow JONES (US) | 44,055.03 | 489.63 | -1.10% |
| FTSE 100 | 8,550.01 | 123.95 | -1.43% |
| HKSE | 20,217.26 | 7.85 | -0.04% |
| NASDAQ | 19,263.08 | 364.36 | -1.86% |
| Nikkei 225 | 38,520.09 | 1,052.40 | -2.66% |
| NZX 50 Index | 12,810.32 | 184.69 | -1.42% |
| S&P 500 | 5,948.86 | 91.67 | -1.52% |
| S&P/ASX 200 | 8,379.40 | 152.90 | -1.79% |
| SSE Composite Index | 3,250.60 | 2.03 | -0.06% |